Articles from Weave Bio

Weave Bio, the leader in AI-native regulatory automation for drug development, today announced new global submission capabilities that give drug development teams one connected platform for every regulatory filing across a program’s lifecycle, from an Investigational New Drug (IND) application and Clinical Trial Application (CTA) to a New Drug Application (NDA) and beyond. Available immediately, the enhancements establish a single source of truth across jurisdictions, with AI accelerating every step from data extraction to submission.

Weave Bio, the leader in AI-native regulatory automation for drug development, and strategic partner Parexel, a leading global clinical development partner, today announced that the Weave platform now supports New Drug Application (NDA) submissions, advancing the company’s coverage of the full regulatory lifecycle.

Weave Bio, the leader in AI-native regulatory automation, today announced the formation of its inaugural Strategic Advisory Board (SAB). Bringing together senior executives and thought leaders with expertise spanning pharma regulatory strategy and operations, health authority policy and practice, capital markets, and academic research, the SAB will serve as a strategic forum to guide the evolution of the Weave Platform and advance the responsible adoption of AI across the life sciences regulatory ecosystem.

Weave Bio, the leader in AI-native regulatory automation, today announced the launch of HAQ Manager, a breakthrough capability that applies artificial intelligence (AI) and workflow automation to accelerate responses to Health Authority Questions (HAQs) during regulatory review. This launch extends Weave's platform beyond submission preparation into the critical post-submission review phase, helping organizations navigate one of the most time-pressured and consequential stages of drug development.

Weave Bio, a pioneer in AI-native regulatory automation management solutions, today announced its $20 million Series A funding, bringing the company’s total capital raised to $36 million. The round was led by USVP, with participation by Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital.

Weave Bio, an AI-native life sciences platform company, today announced that its AutoIND solution has received the “BioTech AI Innovation of the Year” award in the fourth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe.

Weave Bio, an AI-native life sciences platform company, announced the public release of its flagship offering, AutoIND, and seed funding of $10M co-led by Innovation Endeavors and Magnetic Ventures. AutoIND automates and accelerates the preparation, writing, and review process for INDs, and it is the first offering on Weave’s comprehensive Regulatory Automation and Lifecycle Management (ReALM) platform.